Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, today released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, discussing his experience with Nociscan in evaluating chronic low back pain. The video is available here.
Mr. Sutcliffe, who has over 30 years of experience and serves as Lead Clinician at The London Spine Clinic, noted that Nociscan provides an additional layer of insight that complements traditional imaging. "Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain," he said.
To date, nearly 100 Nociscans have been performed at The London Clinic. Nociscan is a non-invasive solution that uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain, helping physicians differentiate between painful and non-painful discs in the lumbar spine. This growing utilization reflects sustained physician engagement and integration into routine clinical practice.
Brent Ness, CEO of Aclarion, stated, "Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain."
Chronic low back pain affects approximately 266 million people worldwide. Clinical data have demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. For more information, visit the company's latest news or find a Nociscan center via the site map.
